Supplementary Appendix

Supplement to: Sperling MA, Laffel LM. Current management of glycemia in children with type 1 diabetes mellitus.
N Engl J Med 2022;386:1155-64. DOI: 10.1056/NEJMcp2112175

This appendix has been provided by the authors to give readers additional information about the work.
SUPPLEMENTARY APPENDIX, CURRENT MANAGEMENT OF GLYCEMIA IN
CHILDREN WITH TYPE 1 DIABETES MELLITUS
MARK A SPERLING MD and LORI M LAFFEL MD MPH

Table of Contents:

Table S1. Examples of Continuous Glucose Monitoring Devices. Page 2

TABLE S1 CONTINOUS GLUCOSE MONITORING (CGM) DEVICES
COMPANY CGM ACCURACY CALIBRATION LIFE SMART FEATURES LIMITATIONS
SYSTEM MARD% DAYS

ABBOTT FREESTYLE 11.4 NOT REQUIRED 14 Trend Arrows, Rate Sensor must be
of change alert, scanned; confirm via
LIBRE 2
hypo/hyperglycemia SMBG if hypoglycemia
alarm, remote -Approved ages 4+
monitoring years
MEDTRONIC GUARDIAN Adults 9.2 Q12 HOURLY 7 Trend arrows, rate Approved for use with
Children 9.7 of change alerts, insulin pump and as
SENSOR3
Accuracy may hypo/hyperglycemia adjunctive to blood
depend on alarm, integrates glucose monitoring
site of with Medtronic -Approved ages 2+
insertion pumps years
DEXCOM G6 10 NOT REQUIRED 10 As above plus Confirm via SMBG
wireless when symptoms do
communication not match level
with up to 5 devices -Approved ages 2+
years
SENSEONICS EVERSENSE 8.5-9.1 REQUIRED at least 180 Trend arrows, rate Must be inserted and
of change; removed by a
E3 Q24 HOURLY
hyper/hypo alarms physician
-Approved ages 18+ in
USA

CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose; MARD, mean absolute relative difference.
Adapted from Cappon G et al. Continuous glucose monitoring systems for diabetes management: A review of technologies and
applications. Diabetes Metab J 2019; 43(4):383-397. Garg, S.K., et al., Evaluation of Accuracy and Safety of the Next-Generation Up
to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther.
2022; 24(2):84-92.